Anthem Biosciences Limited has informed the Exchange about Transcript
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anthem Biosciences reported FY26 consolidated revenue of Rs. 2,124 crore (up 18% YoY), with CRDMO contributing Rs. 1,773 crore (83% of revenue, 18% growth) and specialty ingredients Rs. 352 crore. EBITDA was Rs. 990 crore with 43.4% margins (up 420 bps), and PAT was Rs. 592 crore (26% margins, up 31% YoY). Q4 FY26 was the highest-ever revenue quarter at Rs. 611 crore with 48.1% EBITDA margins. Net cash position is Rs. 1,375 crore. Management flagged that destocking headwinds from FY26 are now largely behind them with restocking underway, and GLP-1 represents a significant future opportunity for import substitution in India. Unit 4 expansion (Phase 1: Rs. 1,200 crore over FY27–FY28) will double custom synthesis capacity to ~790 kiloliters. Commercial portfolio grew to 14 molecules (4 new in FY26), with 10 Phase 3 programs and 100+ early-stage programs ongoing. Management refrained from giving formal FY27 guidance but aspires to maintain ~20% historical revenue growth trajectory.
Strong profitability expansion (EBITDA margins crossed 43%) with cash-rich balance sheet positions Anthem well for its large Unit 4 capex cycle. The destocking cycle appearing over and a growing Phase 3 pipeline (10 molecules, all from emerging biotech) provide visibility into sustained growth, though the lack of formal near-term guidance may limit near-term re-rating.